FCGR3A and cancer: haNK, a NK-92 cell line engineered with high-affinity FcγRIIIa (158V) allele (Gleason et al., 2012), has been tested in phase I and II clinical trials, either alone or in combination with anti-PD-L1 antibody (avelumab), a cancer vaccine, or super-IL-15.